Market Size of Europe Kidney Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Europe Kidney Cancer Therapeutics & Diagnostics Market Analysis
The Europe Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.7% during the forecast period. The major factors driving the growth of the market in the Europe region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in Germany, there were about 16,416 new kidney cancer cases in 2018 and the mortality was approximately 8,450 cases.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Europe kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.
Europe Kidney Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, kidney cancer is a type of cancer that starts in kidney cells. The kidney cancer therapeutics and diagnostics involve therapy and diagnostics methods that are used for the treatment of renal cancer. The Europe kidney cancer therapeutics & diagnostics market is segmented by cancer type, component and geography.
| By Cancer Type | |
| Clear cell RCC | |
| Papillary RCC | |
| Chromophobe RCC | |
| Urothelial carcinoma/Transitional cell carcinoma | |
| Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC) |
| By Component | |||||||||||||
| |||||||||||||
|
| Geography | ||||||||
|
Europe Kidney Cancer Therapeutics & Diagnostics Market Size Summary
The Europe Kidney Cancer Therapeutics and Diagnostics Market is poised for significant expansion, driven by an increasing incidence of kidney cancer and heightened research and development investments by pharmaceutical companies. Lifestyle changes, such as increased smoking, alcohol consumption, and obesity due to sedentary habits, have contributed to the rising prevalence of kidney cancer in the region. This trend is reflected in the growing number of cases and the advanced stages at which many are diagnosed. The market is characterized by the presence of various diagnostic procedures and treatment therapies, including the notable introduction of FOTIVDA for advanced renal cell carcinoma treatment in several European countries.
The competitive landscape of the Europe Kidney Cancer Therapeutics and Diagnostics Market is moderately consolidated, with key players like Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Amgen Inc, Novartis AG, Pfizer Inc, and Seattle Genetics leading the charge. These companies are actively engaged in product innovation and research activities to develop advanced technologies, which are crucial for market growth. The market's expansion is further supported by the high prevalence of kidney cancer and the ongoing advancements in therapeutic and diagnostic solutions, positioning it for continued growth over the forecast period.
Europe Kidney Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Number of Kidney Cancer Cases
-
1.2.2 Increased R&D Expenditure of Pharmaceutical Companies
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated with Treatment
-
1.3.2 Preference for Generic Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Clear cell RCC
-
2.1.2 Papillary RCC
-
2.1.3 Chromophobe RCC
-
2.1.4 Urothelial carcinoma/Transitional cell carcinoma
-
2.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
-
-
2.2 By Component
-
2.2.1 Drugs
-
2.2.1.1 Therapeutic Class
-
2.2.1.1.1 Targeted Therapy
-
2.2.1.1.2 Immunotherapy
-
2.2.1.1.3 Other Therapeutic Class
-
-
2.2.1.2 By Pharmacologic Class
-
2.2.1.2.1 Angiogenesis Inhibitors
-
2.2.1.2.2 Monoclonal Antibodies
-
2.2.1.2.3 mTOR Inhibitors
-
2.2.1.2.4 Cytokine Immunotherapy (IL-2)
-
-
-
2.2.2 Diagnostics
-
2.2.2.1 Biopsy
-
2.2.2.2 Imaging Tests
-
2.2.2.3 Blood Tests
-
2.2.2.4 Other Diagnostics
-
-
-
2.3 Geography
-
2.3.1 Europe
-
2.3.1.1 Germany
-
2.3.1.2 United Kingdom
-
2.3.1.3 France
-
2.3.1.4 Italy
-
2.3.1.5 Spain
-
2.3.1.6 Rest of Europe
-
-
-
Europe Kidney Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current Europe Kidney Cancer Therapeutics & Diagnostics Market size?
The Europe Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in Europe Kidney Cancer Therapeutics & Diagnostics Market?
F. Hoffmann-La Roche Ltd, Bayer AG, Amgen Inc, Abbott Laboratories and Bristol-Myers Squibb Company are the major companies operating in the Europe Kidney Cancer Therapeutics & Diagnostics Market.
